CUR vs. SCNI, TCBP, SQZ, WINT, ELOX, NSTGQ, ATNF, SXTC, ADTX, and QNRX
Should you be buying Neuralstem stock or one of its competitors? The main competitors of Neuralstem include Scinai Immunotherapeutics (SCNI), TC Biopharm (TCBP), SQZ Biotechnologies (SQZ), Windtree Therapeutics (WINT), Eloxx Pharmaceuticals (ELOX), NanoString Technologies (NSTGQ), 180 Life Sciences (ATNF), China SXT Pharmaceuticals (SXTC), Aditxt (ADTX), and Quoin Pharmaceuticals (QNRX). These companies are all part of the "medical" sector.
Neuralstem (NASDAQ:CUR) and Scinai Immunotherapeutics (NASDAQ:SCNI) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their community ranking, institutional ownership, valuation, earnings, profitability, analyst recommendations, dividends, media sentiment and risk.
In the previous week, Scinai Immunotherapeutics had 4 more articles in the media than Neuralstem. MarketBeat recorded 4 mentions for Scinai Immunotherapeutics and 0 mentions for Neuralstem. Scinai Immunotherapeutics' average media sentiment score of 0.39 beat Neuralstem's score of 0.00 indicating that Scinai Immunotherapeutics is being referred to more favorably in the news media.
Scinai Immunotherapeutics has a net margin of 0.00% compared to Neuralstem's net margin of -39,417.64%. Scinai Immunotherapeutics' return on equity of 0.00% beat Neuralstem's return on equity.
Neuralstem received 278 more outperform votes than Scinai Immunotherapeutics when rated by MarketBeat users.
Neuralstem has a beta of 1.81, suggesting that its share price is 81% more volatile than the S&P 500. Comparatively, Scinai Immunotherapeutics has a beta of 2.5, suggesting that its share price is 150% more volatile than the S&P 500.
38.3% of Neuralstem shares are held by institutional investors. Comparatively, 58.4% of Scinai Immunotherapeutics shares are held by institutional investors. 5.4% of Neuralstem shares are held by insiders. Comparatively, 60.9% of Scinai Immunotherapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Neuralstem has higher revenue and earnings than Scinai Immunotherapeutics.
Summary
Scinai Immunotherapeutics beats Neuralstem on 8 of the 11 factors compared between the two stocks.
Get Neuralstem News Delivered to You Automatically
Sign up to receive the latest news and ratings for CUR and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CUR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartThis chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
Neuralstem Competitors List
Related Companies and Tools